FDA label
What is Auryxia used for?
Auryxia contains tetraferric tricitrate decahydrate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Auryxia lists 2 uses: Hyperphosphatemia in Chronic Kidney Disease on Dialysis; Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Auryxia?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Auryxia, tablet, film coated
Indications and Usage, quoted from the label by Akebia Therapeutics, Inc. (NDA205874). Cross-references to other label sections are left out.
Hyperphosphatemia in Chronic Kidney Disease on Dialysis
Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.
Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis
Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.
Source: DailyMed label, set id aadd18e0-3752-11e4-8510-0800200c9a66, version 27, effective December 4, 2024. NDC 59922-631, one of 1 listing for this product.
Questions
What is Auryxia used for?
The FDA label for Auryxia lists 2 uses: Hyperphosphatemia in Chronic Kidney Disease on Dialysis; Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis.
What drug class is Auryxia?
FDA lists tetraferric tricitrate decahydrate in the Parenteral Iron Replacement and Phosphate Binder established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.